Skip to main content
Article thumbnail
Location of Repository

A pilot open label, single dose trial of fenobam in adults with fragile X syndrome

By E Berry-Kravis, D Hessl, S Coffey, C Hervey, A Schneider, J Yuhas, J Hutchison, M Snape, M Tranfaglia, D V Nguyen and R Hagerman
Topics: Original Articles
Publisher: BMJ Publishing Group
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. Altered synaptic plasticity in a mouse model of fragile X mental retardation.
    2. Behavioural equivalents of anxiety in children with fragile X syndrome: parent and teacher report.
    3. Brain structure and functions of FMR1 protein.
    4. Correction of fragile X syndrome in mice.
    5. (2004). Correlates across the structural, functional, and molecular phenotypes of fragile X syndrome. Ment Retard Dev Disabil Res Rev
    6. De Zeeuw CI. Deletion of FMR1 in purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in fragile X syndrome.
    7. Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial.
    8. Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity.
    9. Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors.
    10. Fragile X mental retardation protein is necessary for neurotransmitter-activated protein translation at synapses.
    11. (1991). Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome.
    12. Local protein synthesis and spine morphogenesis: fragile X syndrome and beyond.
    13. Metabotropic glutamate receptor activation regulates fragile X mental retardation protein and FMR1 mRNA localization differentially in dendrites and at synapses.
    14. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome.
    15. (1980). Phase II double-blind controlled study of a new anxiolytic, fenobam (McN-3377) vs placebo. Curr Ther Res
    16. (2008). Prepulse inhibition in fragile X syndrome: feasibility, reliability, and implications for treatment.
    17. Prolonged epileptiform discharges induced by altered group I metabotropic glutamate receptormediated synaptic responses in hippocampal slices of a fragile X mouse model.
    18. Rescue of behavioral phenotype and neuronal protrusion morphology
    19. (2004). Sensorimotor gating abnormalities in young males with fragile X syndrome and FMR1-knockout mice. Mol Psychiatry
    20. (1978). The clinical and quantitative EEG effects and plasma levels of fenbam (McN-3377) in subjects with anxiety: an open rising dose tolerance and efficacy study. Curr Ther Res
    21. The effects of methylphenidate on prepulse inhibition during attended and ignored prestimuli among boys with attentiondeficit hyperactivity disorder. Psychopharmacology (Berl)
    22. (1993). The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation.
    23. The fragile X mental retardation protein and group I metabotropic glutamate receptors regulate levels of mRNA granules in brain.
    24. The fragile X prevalence paradox.
    25. (2004). The mGluR theory of fragile X mental retardation. Trends Neurosci
    26. The relationship between sensorimotor gating and clinicalimprovementinacutelyillschizophreniapatients.Schizophrres2007;89:225–31.
    27. Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebocontrolled study.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.